Introduction {#Sec1}
============

Migraine is a frequent condition in children, with a prevalence ranging from 3% in younger school-age children to approximately 20% in older adolescents \[[@CR1]\].

The current classification system for primary migraine (Table [1](#Tab1){ref-type="table"}) was published by the International Headache Society in 2004 and is known as the International Classification of Headache Disorders (ICHD-II) \[[@CR2]\]. The ICHD-II for the diagnosis of pediatric migraine has been shown to have a sensitivity of 84% \[[@CR3]\]. One of the limitations related to the use of ICHD-II criteria in the diagnosis of pediatric migraine is the difficulty children encounter in describing the features of headache and any associated symptoms. Moreover, as the features of headache may change from preschool age to adolescence \[[@CR4]\], some authors have suggested modifying the criteria for headache diagnosis in childhood \[[@CR5]\].Table 1International headache society classification of migraine (ICHD-II)(1) Migraine without aura(2) Migraine with aura a. Typical aura with migraine headache b. Typical aura with non-migraine headache c. Typical aura without headache d. Familial hemiplegic migraine e. Sporadic hemiplegic migraine f. Basilar-type migraine(3) Childhood periodic syndromes that are commonly precursors of migraine a. Cyclic vomiting b. Abdominal migraine c. Benign paroxysmal vertigo of childhood(4) Retinal migraine(5) Complications of migraine(6) Probable migraine

Despite the high frequency of migraine and the severity of attacks in the pediatric population, there is a serious lack of controlled data available in the literature on migraine therapy. Few randomized placebo-controlled trials on acute-phase or preventive drugs have yielded successful results in pediatric headache patients. Moreover, the high placebo response in some trials makes it difficult to prove the efficacy of the drug being studied \[[@CR6]\].

The most recent practice guidelines for the therapy of pediatric migraine were published by the Italian Society for the study of Headache (SISC, 2003), the French Society for the study of Migraine and Headache (2004) and the American Academy of Neurology (AAN, 2004) \[[@CR7]--[@CR9]\]. The aims of this review were to update these guidelines \[[@CR7]--[@CR9]\], incorporating the results from randomized controlled trials (RCTs), clinical controlled trials (CCTs), open-label (OL) studies, meta-analyses and reviews published on this hot topic since 2004. Owing to the lack of strong evidence in this field of research, in certain cases we also mentioned pilot non-controlled studies, case series and expert opinions. Lastly, findings regarding pharmacological therapies were reviewed and the recommendations were categorized into different levels (A--C) (Table [2](#Tab2){ref-type="table"}) \[[@CR10]\].Table 2Levels of evidence for the treatment of migraineLevel A: two or more clinically controlled, randomized studies carried out according to good clinical practice (GCP), versus placebo or versus active treatment of proven efficacyLevel B: one clinically controlled, randomized study carried out according to GCP or more than one well-designed clinical case--control study or cohort studyLevel C: favorable judgment of two-third of the Ad Hoc Committee members, historical controls, non-randomized studies, case reports

Literature search strategy {#Sec2}
==========================

In December 2009, an extensive search was undertaken to identify currently available headache treatment guidelines (acute phase and prophylaxis). Moreover, we identified any RCTs, CCTs, OL studies, meta-analyses, reviews and articles that were either published or "in press" in the last 6 years (from 2004 to 2009) using the keywords "migraine and treatment or therapy" (293 papers), "migraine and prophylaxis" (66 papers) and "migraine and guidelines" (4 papers). Any relevant papers published in the same period that were not selected by these keywords were also taken into account. "PubMed" was used as the source for our search, which was not subjected to any language restriction, and any citations found in relevant studies were investigated. Our search was limited to the pediatric age group (0--18 years), although any articles that included adults but contained a high proportion of persons under the age of 18 years were considered. The only headache exclusion criteria adopted were the words "symptomatic or secondary". After the search and selection of the data was completed, two reviewers independently extracted the data, while a third reviewer solved any discrepancies.

The search identified 42 studies. One reviewer scanned these to eliminate any irrelevant studies. Three reviewers scanned the remaining 25 studies and the 30 relevant citations identified within these studies.

Pediatric migraine treatment: general approach {#Sec3}
==============================================

Appropriate treatment for children with migraine requires an individually tailored strategy, based on both pharmacological and non-pharmacological measures, defined according to the degree of disability caused by the headache \[[@CR11]\]. The choice of therapy must be based on the symptoms, response to treatment and headache "impact", which reflects an individual patient's frequency, duration, intensity, functional disability, quality of life, comorbidity and pain tolerance \[[@CR12]\].

The impact of migraine can be assessed in adults by using the migraine disability assessment (MIDAS) questionnaire \[[@CR13]\]. However, since the MIDAS is not suitable for children because their lifestyles differ from those of adults, the pediatric migraine disability assessment (PedMIDAS) was developed. The range of the scoring system, which is based on the patient's disability, is wider than that of the MIDAS because children are more likely to omit activities. PedMIDAS can be used clinically to identify the impact of migraine in individual pediatric patients and assess their response to treatment \[[@CR14]\].

The MIDAS questionnaire can also be used to stratify adult patients into groups with different treatment needs according to the degree of headache-related disability. Stratified care was developed as an alternative to the step-care approach, which is instead preferred in the treatment of pediatric migraine, and places patients on non-specific medication that is gradually increased until effective relief is achieved \[[@CR15]\].

The pharmacological treatment of pediatric migraine includes: acute or episodic medications and prophylactic or preventive agents \[[@CR12]\].

Acute treatments of migraine {#Sec4}
============================

The aim of acute treatment should be a rapid response, resulting in a prompt return to normal activity and no relapse. To date, the only treatments that have been approved for migraine attacks in adolescents are almotriptan, by the US Food and Drugs Administration (FDA), and nasal sumatriptan and zolmitriptan, by the European Medicines Agency (EMEA) \[[@CR19]\].

Analgesics {#Sec5}
----------

Ibuprofen is effective and should be considered for the acute treatment of migraine in children (Level A) \[[@CR7]--[@CR9]\].

Acetaminophen is probably effective and should be considered for the acute treatment of migraine in children (Level B) \[[@CR7]--[@CR9]\].

Ibuprofen (10 mg/kg) and acetaminophen (15 mg/kg) were more effective than placebo; the effect yielded by ibuprofen at 2 h was better than that of acetaminophen (68 vs. 54% of children relieved) and lasted longer. Neither drug had significant side effects \[[@CR11], [@CR17]\].

Recently Evers et al. \[[@CR18]\] found that ibuprofen 200--400 mg was more effective than placebo in providing pain relief after 2 h (28% for placebo vs. 69% for ibuprofen; *P* \< 0.05).

The efficacy and safety of other non-steroid anti-inflammatory drugs (NSAIDs) (e.g., acetylsalicylic acid, diclofenac, naproxen, mefenamic acid) in the treatment of migraine in children and adolescents have not yet been assessed \[[@CR11]\].

Triptans {#Sec6}
--------

The family of triptans has improved the treatment of acute migraine in adults and several studies have demonstrated the safety of such drugs in children \[[@CR1]\]. In 2009, the FDA approved almotriptan for the treatment of adolescent migraine, while nasal sumatriptan and zolmitriptan were approved for the acute treatment of adolescent migraine by the EMEA \[[@CR19]\].

### Sumatriptan {#Sec7}

Sumatriptan nasal spray (NS) is effective and should be considered for the acute treatment of migraine in adolescents (Level A) \[[@CR7]--[@CR9]\].

Callenbach et al. \[[@CR20]\] published a review of all controlled studies that evaluated the efficacy and safety of sumatriptan NS in the pediatric migraine population. Their review included seven trials, most of which included children aged 12--17 years as their study subjects. Intranasal sumatriptan was effective in relieving headache after both 1 and 2 h in all the studies, the response rates being comparable to those found in studies on adults. Four of the studies detected a significant difference in relief between sumatriptan and placebo (Table [3](#Tab3){ref-type="table"}). Moreover, sumatriptan NS revealed a positive effect on vomiting and photophobia/phonophobia. The main side effect was bad taste. Effective doses are 10 mg for children weighing \<40 kg and 20 mg for children weighing \>40 kg \[[@CR11], [@CR17], [@CR21]\].Table 3Symptomatic drugs evaluated in placebo-controlled and open clinical trialsDrugEvidence levelStudy designAges (years)*n*Primary end point: pain relief (hours)Responders (%)Placebo responses (%)*P* valueAuthor/Pubdate/Ref.Ibuprofen 10 mg/kgArDBPC4--168826837\<0.05Hamalainen et al., 1997 \[[@CR10], [@CR16]\] 7.5 mg/kgDBPC6--1284276530.006Lewis et al., 2002 \[[@CR10], [@CR16]\] 200--400 mgDBPCCO6--183226928\<0.05Evers et al., 2006 \[[@CR21]\]Acetaminophen 15 mg/kgBrDBPC4--168825437\<0.05Hamalainen et al., 1997 \[[@CR10], [@CR16]\]Sumatriptan nasal 20 mgArDBPC6--101428642.80.03Ueberall et al., 1999 \[[@CR18]\] 5--10--20 mgrDBPC12--17510263--6653\<0.05Winner et al., 2000 \[[@CR18]\] 10--20 mgrDBPCCO8--1783264390.003Ahonen et al., 2004 \[[@CR18]\] 20 mgrDBPC12--1773816152nsWinner et al., 2006 \[[@CR19]\]Sumatriptan oral 50--100 mgCrDBPCCO8--162323022nsHamalainen et al., 1997 \[[@CR10], [@CR16]\]Sumatriptan subcutaneous 3--6 mgCOL6--1617264----MacDonald, 1994 \[[@CR10], [@CR16]\] 0.06 mg/kgOL6--1850278----Linder, 1996 \[[@CR10], [@CR16]\]Zolmitriptan oral 2.5--5 mgCOL12--1738288----Linder et al., 2000 \[[@CR10], [@CR16]\] 2.5 mgDBPCCO6--183226228*P* \< 0.05Evers et al., 2006 \[[@CR21]\] 2.5--5--10 mgrDBPC12--17850253--5758nsRothner et al., 2006 \[[@CR20]\]Zolmitriptan NS 5 mgBSB-DBPC12--17171158.143.3*P* \< 0.05Lewis et al., 2007 \[[@CR22]\]Rizatriptan oral 5 mgCrDBPC12--1729626656nsWinner et al., 2002 \[[@CR10], [@CR16]\] 5 mgrDBPC12--17234268.268.8nsVisser et al., 2004 \[[@CR23]\] 5 mgOL12--17686277----Visser et al., 2004 \[[@CR23]\] 5--10 mgrDBPC6--179627436*P *= 0.001Ahonen et al., 2006 \[[@CR24]\]Almotriptan oral 6.25--12.5 mgBOL11--1715285----Charles et al., 2006 \[[@CR25]\] 6.25--12.5--25 mgrDBPC12--17866267--7355*P* \< 0.001Linder et al., 2008 \[[@CR26]\]Eletriptan oral 40 mgCDBPC12--1726725757nsWinner et al., 2007 \[[@CR27]\]Naratriptan oralCDBPC12--17300464--7265nsRothner et al., 1997 \[[@CR10], [@CR16]\]*DBPC* double-blind placebo-controlled, *DBPCCO* double-blind placebo-controlled crossover, *rDBPC* randomized double-blind placebo controlled, *HA* headache, *OL* open-label, *RR* retrospective review

The most recent RCT was conducted by Winner et al. on 738 adolescent subjects (mean age 14 years) treated with sumatriptan NS (5 and 20 mg). Sumatriptan NS 20 mg provided significantly greater headache relief than placebo at 30 min (42 vs. 33%, respectively; *P* = 0.046) and 2 h (68 vs. 58%; *P* = 0.025) post-dose, but did not reach statistical significance at either 1 h (61 vs. 52%; *P* = 0.087) or for sustained headache relief from 1 to 24 h (*P* = 0.061). Significant differences (*P* \< 0.05) in favor of sumatriptan NS 20 mg over placebo were observed for several secondary efficacy endpoints, including sustained relief from 2 to 24 h \[[@CR21]\].

No data are available to support or refute the use of any oral or subcutaneous sumatriptan preparations in children or adolescents (Level U) \[[@CR7]--[@CR9]\] because such preparations have yielded less positive data owing to their prominent side and placebo effects \[[@CR11], [@CR17]\].

### Zolmitriptan {#Sec8}

Studies in which oral zolmitriptan was compared with placebo have yielded contrasting results \[[@CR11], [@CR21], [@CR22]\]. Since 2004, two large studies evaluating the efficacy and tolerability of oral zolmitriptan in pediatric migraine have been published \[[@CR22], [@CR23]\]. The first compared zolmitriptan at three different doses (2.5, 5, and 10 mg) with placebo in 640 outpatients aged 12--17 years. Two-hour headache response rates were 54% (10 mg), 53% (5 mg) and 57% (2.5 mg) for zolmitriptan, and 58% for placebo. Two-hour pain-free rates were 25% (10 mg), 19% (5 mg), and 23% (2.5 mg) for zolmitriptan, and 20% for placebo. Zolmitriptan was well tolerated, with a tolerability profile similar to that observed in adults. The authors hypothesized that the similar efficacy observed in zolmitriptan and placebo may be the result of the high placebo response rate and the shorter duration of headache pain in adolescents if compared with adults \[[@CR22]\].

Evers et al. conducted a double-blind, placebo-controlled, cross-over study in which patients received placebo, zolmitriptan 2.5 mg, and ibuprofen 200--400 mg, each being used to treat one of three consecutive migraine attacks. Pain relief rates after 2 h were 28% for placebo, 62% for zolmitriptan, and 69% for ibuprofen (placebo vs. zolmitriptan *P* \< 0.05; placebo vs. ibuprofen *P* \< 0.05). Both drugs were well tolerated, only mild side effects being reported \[[@CR23]\]. The 2-h headache response rates for zolmitriptan were similar to those observed in the previous study, while the placebo rate was lower. A possible reason for the low placebo rate might be that children and adolescents with severe migraine were enrolled in the second study. If compared with the other triptan trials in which the patients' characteristics were similar, the duration and frequency of attacks in the study by Evers et al. \[[@CR23]\] were higher, resembling those observed in adulthood migraine.

Lewis et al. conducted a novel, placebo-challenge study to evaluate the efficacy and tolerability of zolmitriptan NS in adolescent migraine. A total of 248 adolescents was studied in a randomized, double-blind, placebo-controlled, two-attack, cross-over trial with a single-blind placebo challenge. Seventy-seven patients responded to the placebo challenge and did not thus continue the study. Of the remaining 171 patients, zolmitriptan produced significantly higher headache response rates than placebo 1 h post-dose (58.1 vs. 43.3%; *P* \< 0.02), with an onset of action occurring as early as 15 min. Zolmitriptan also produced a significant pain-free response at 1 h (27.7 vs. 10.2% in the placebo group, *P* \< 0.001), proving to be significantly superior to placebo in improving pain intensity, pain-free rates, sustained resolution of headache and resolution of associated migraine symptoms. Treatment with zolmitriptan NS was well tolerated \[[@CR24]\].

### Rizatriptan {#Sec9}

Two recent RCTs compared the efficacy of oral rizatriptan with placebo \[[@CR25], [@CR26]\].

Visser et al. evaluated the short- and long-term efficacy and tolerability of rizatriptan 5 mg in adolescents with migraine. They conducted an rDBPC single-attack study followed by a randomized, 1-year, OL extension, as well as a randomized 1-year OL study. In the single-attack study, the proportion of patients in whom pain was relieved at 2 h was not significantly different in the rizatriptan 5 mg (68.2%) and placebo (68.8%) groups. In the multiple attack studies, pain relief at 2 h was achieved in a significantly higher number of attacks treated with a rizatriptan 5-mg tablet (77%) or with a rizatriptan 5-mg wafer (77%) than by means of standard care (64%). Rizatriptan 5 mg was well tolerated in adolescents during both short- and long-term use \[[@CR25]\].

The second study investigated the efficacy of oral rizatriptan (5 and 10 mg) and the consistency of the response over two treated migraine attacks in children and adolescents over 6 years of age. Two doses of rizatriptan and a matching placebo were administered at home during three attacks. Headache relief at 2 h was achieved twice as often after each rizatriptan treatment (first 74%; second 73%) as after placebo (36%) (*P* = 0.001). The efficacy of rizatriptan was constant over the two treated attacks, while the findings were similar regardless of the dose administered (5 and 10 mg). No serious adverse effects were observed. The efficacy and the tolerance of rizatriptan in children below 12 years of age did not differ from those observed in adolescents \[[@CR26]\].

### Almotriptan {#Sec10}

Two studies investigated the efficacy and safety of almotriptan in adolescents with migraine \[[@CR27], [@CR28]\].

The first is a small OL placebo-controlled trial. Fifteen patients aged 11--17 years with a history of migraine were treated with almotriptan at doses ranging from 6.25 to 12.5 mg. Almotriptan was effective in 13 patients, with no significant adverse effects being reported \[[@CR27]\].

The FDA approval of almotriptan for the acute treatment of migraine headache in adolescents was based on data from a recent randomized placebo-controlled trial. Linder et al. assessed the efficacy and safety of almotriptan 6.25, 12.5, and 25 mg versus placebo for acute migraine treatment in adolescents (866 patients aged 12--17 years). The 2-h pain-relief rates were significantly higher with almotriptan 6.25 mg (71.8%), 12.5 mg (72.9%), and 25 mg (66.7%) than with placebo (55.3%; *P* = 0.001, *P* \< 0.001 and *P* = 0.028, respectively). Age group sub-analysis demonstrated significantly greater 2-h pain-relief rates for patients aged 15--17 years, a significantly lower incidence of photophobia and phonophobia 2 h after almotriptan 12.5 mg administration in patients aged 15--17 years than in the placebo group, and a significantly lower incidence of photophobia following almotriptan 12.5 mg administration in patients aged 12--14 years than in the placebo group \[[@CR28]\].

### Eletriptan {#Sec11}

A multicenter, double-blind, parallel-group, placebo-controlled trial compared 40 mg of oral eletriptan with placebo for the treatment of migraine in adolescent patients aged 12--17 years. Drug efficacy was evaluated in patients 2 h post-dose. There was no significant difference in the 2 h headache response between eletriptan 40 mg and placebo (57 vs. 57%), nor was any significant improvement observed in any of the outcomes 1 or 2 h post-dose. By contrast, eletriptan 40 mg proved to be significantly more effective in reducing headache recurrence than placebo within 24 h (11 vs. 25%, *P* = 0.028), with post hoc analyses showing statistically significant differences for sustained headache response rates (52 vs. 39%; *P* = 0.04) and sustained pain-free response rates (22 vs. 10%; *P* = 0.013) \[[@CR29]\].

Antiemetics {#Sec12}
-----------

There is one recent randomized-controlled study on pediatric migraine therapy in the emergency room that compared the efficacy of prochlorperazine with that of ketorolac. In that study, prochlorperazine was found to be more effective than ketorolac as regards the primary outcome, which was a decrease in the intensity of the migraine by 50% or complete relief within 1 h: 28/33 (85%) versus 16/29 (55%), respectively \[[@CR30]\].

The drugs and acute-phase treatment outcome in pediatric migraine patients are shown in Table [3](#Tab3){ref-type="table"}.

Prophylactic treatment of pediatric migraine {#Sec13}
============================================

Prophylactic pharmacological treatment may be considered when headache frequency exceeds three or four episodes per month and/or the attacks are so severe and prolonged that they interfere with school or normal activities. The goals of prophylactic therapy include: reducing attack frequency, severity and duration, improving responsiveness to treatment of acute attacks, improving function and quality of life, and reducing disability \[[@CR31]\].

Calcium channel blockers {#Sec14}
------------------------

### Flunarizine {#Sec15}

The Italian, French and AAN practice parameters on the management of pediatric migraine (2004) and the Cochrane review (2003) suggest that the calcium channel blocker, flunarizine, is likely to be effective as preventive therapy and may be considered for this purpose (Level b) \[[@CR9], [@CR32]\].

Although it is not available in the United States, flunarizine has yielded good results in several controlled trials and has a proven efficacy (5 mg bedtime dose) in reducing headache frequency and headache duration. The main side effects are daytime sedation and weight gain \[[@CR10], [@CR33]\].

Antidepressants {#Sec16}
---------------

### Amitriptyline {#Sec17}

Although the efficacy of amitriptyline in pediatric migraine has never been assessed in RCTs, it remains one of the most widely used agents. Starting doses of 5--10 mg at bedtime may gradually be increased to 1 mg/(kg day). Cardiac abnormalities and depression represent a contraindication for the use of this drug \[[@CR1], [@CR11], [@CR31]\].

Antiepileptic drugs {#Sec18}
-------------------

Topiramate, valproate, levetiracetam and gabapentin may play increasingly important roles in pediatric migraine. In the light of current views on the pathophysiology of migraine, particularly as regards the primary neuronal initiation and propagation through cortical excitation, and subsequent "spreading depression," anticonvulsants may play an intriguing, though not yet fully defined, role \[[@CR33]\].

### Topiramate {#Sec19}

Recent studies have shown that topiramate is effective in reducing headache frequency and disability in adolescents (Table [4](#Tab4){ref-type="table"}) \[[@CR34]--[@CR39]\].Table 4Prophylactic drugs evaluated in placebo-controlled and open clinical trialsDrugEvidence levelStudy designAges (years)*n*Drug response rate (%)Placebo response rate (%)*P* value (primary endpoint)ReferenceFlunarizine 5 mgADBPC7--14427619*P* \< 0.001 (freq and durat)Sorge et al., 1985 \[[@CR1], [@CR10]\] 5 mgOL10--131266----Guidetti et al., 1987 \[[@CR1], [@CR10]\] 5 mgDBPC CO5--11636733*P* \< 0.001 (freq) *P* \< 0.01 (durat)Sorge et al., 1988 \[[@CR1], [@CR10]\]Nimodipine 10--20 mgCDBPCCO7--18371515ns (freq)Battistella et al., 1990 \[[@CR1], [@CR10]\]Propanolol 60--120 mgCDBCO7--16288214*P* \< 0.001 (freq)Ludvigsson et al., 1974 \[[@CR1], [@CR10]\] 80 mgDBPC3--12395855nsForsythe et al. 1984 \[[@CR1], [@CR10]\] 3 mg/kgDBPC6--1228nsnsnsOlness et al., 1987 \[[@CR1], [@CR10]\]TimololCDBPC CO6--13193840nsNoronha et al. 1985 \[[@CR1], [@CR10]\]Clonidine 25--50 μgCDBPC\<15573234nsSillanpaa, 1977 \[[@CR1], [@CR10]\] 0.07--0.1 mgDBPC7--1443nsnsnsSills et al., 1982 \[[@CR1], [@CR10]\]Cyproheptadine 4 mgCRR3--123083----Lewis et al., 2004 \[[@CR32]\]Amitriptyline 1 mg/kgCOL9--1519284----Hershey et al., 2000 \[[@CR1], [@CR10]\] 10 mgRR3--187389----Lewis et al., 2004 \[[@CR32]\]Trazodone 1 mg/(kg day)CDBPC7--18354540nsBattistella et al., 1993 \[[@CR1], [@CR10]\]PizotifenCDBPC CO7--14471516nsGilles et al., 1986 \[[@CR1], [@CR10]\]Topiramate 12.5--225 mgAOL8--157543--59--*P* \< 0.001 (freq)Hershey et al., 2002 \[[@CR1], [@CR10]\] 2--3 mg/kgrDBPC6--1516254.646.9nsWinner et al., 2005 \[[@CR35]\] 50, 100, 200 mgDBPC12--175146--6516*P* = 0.02 (100 mg), *P* = 0.04 (200 mg) (freq)Winner et al., 2006 \[[@CR38]\] 100 mgDBPC8--14449552*P* = 0.02 (freq)Lakshmi et al., 2007 \[[@CR36]\] 100 mgrDBPC12--17858345*P* \< 0.001 (freq)Lewis et al., 2009 \[[@CR37]\] 50--200 mgRR7--203776--*P* \< 0.001 (freq)Cruz et al., 2009 \[[@CR39]\]Valproate 15--45 mg/(kg day)BOL7--164278.5--*P* \< 0.05 (freq)Caruso et al., 2000 \[[@CR1], [@CR10]\] 500--1,000 mg/dayOL9--171083--*P* = 0.002 (freq)Serdaroglu et al., 2002 \[[@CR1], [@CR10]\] 250--1,125 mg/dayOL7--172365--*P* \< 0.05 (freq)Pekalnis et al., 2001 \[[@CR1], [@CR10]\] 10--40 mg/(kg day)rDBPC3--155872--*P* \< 0.05 (freq)Ashrafi et al., 2005 \[[@CR40]\] 250, 500, 1,000 mgrDBPC12--1730036--5146nsApostol et al., 2008 \[[@CR41]\] 500--1,000 mgOL12--17241----\>75% (freq)Apostol et al., 2009 \[[@CR42]\]LevetiracetamBOL193--1752--*P* \< 0.001 (freq)Miller et al., 2004 \[[@CR1], [@CR10]\] 250--1,500 mgOL206--1790--*P* \< 0.001 (freq)Pekalnis et al., 2007 \[[@CR44]\]Gabapentin 15 mg/kgCRR186--1783--*P* \< 0.001 (freq)Belman et al., 2001 \[[@CR1], [@CR10]\]Zonisamide 5.8 mg/kgCOL1210--1766----Pakalnis et al., 2006 \[[@CR45]\]*DBPC* double-blind placebo-controlled, *DBPCCO* double-blind placebo-controlled crossover, *rDBPC* randomized double-blind placebo controlled, *OL* open-label, *RR* retrospective review, *freq* attack frequency, *durat.* attack duration

Since 2004, three double-blind placebo controlled trials \[[@CR34]--[@CR37]\], one pooled analysis of RCTs \[[@CR38]\] and one retrospective review have been published \[[@CR39]\].

Winner et al. \[[@CR35]\] conducted a placebo-controlled trial in 157 children with migraine aged from 6 to 15 years who were randomized in a 2:1 ratio to receive either topiramate \[2 mg/(kg day)\] or placebo. The primary outcome was the change in the mean number of migraine days per month. Topiramate treatment was associated with a mean reduction of 2.6 migraine days per month as compared with 2.0 in the placebo group. The difference between the two groups marginally missed the significance level (*P* = 0.06). Response to topiramate (i.e., \>50% reduction in migraine frequency) was 55 versus 47% in the placebo group. The most common adverse effects were upper respiration tract infection, anorexia, weight decrease, gastroenteritis, paresthesia and somnolence \[[@CR35]\].

Winner et al. \[[@CR38]\] performed a second study in which data from subjects aged 12--17 years who had participated in three previous RCTs with a similar design were pooled. All three previous studies had compared topiramate at a dose of 100 or 200 mg/day with placebo. The primary outcome measure was the median percentage reduction in the monthly migraine frequency. Topiramate at a dose of 100 and 200 mg/day was associated with a statistically significant reduction in migraine frequency when compared with placebo (respectively 63 and 65 vs. 16% for placebo, *P* = 0.02 for topiramate 100 mg/day and *P* = 0.04 for topiramate 200 mg/day). Topiramate at a dose of 50 mg/day was less effective (46% reduction, *P* = 0.07) \[[@CR38]\].

Lewis et al. evaluated the efficacy and safety of topiramate (50 or 100 mg/day) for migraine prevention in 85 adolescents (12--17 years of age). The primary efficacy measure was the reduction in the number of monthly migraine attacks. Topiramate at a dose of 100 mg/day, though not 50 mg/day, resulted in a statistically significant reduction in the monthly migraine attack rate if compared with the placebo group (median 72.2 vs. 44.4%). Topiramate at a dose of 100 mg/day also resulted in a statistically significant reduction in the number of monthly migraine days if compared with the placebo group (83 vs. 45% for placebo) \[[@CR37]\].

A third double-blind placebo-controlled trial was conducted in 44 children with migraine. Twenty-two patients received topiramate (final dose of 100 mg) while 22 received placebos. There was a statistically significant decrease in the mean monthly migraine frequency in the topiramate group as compared with the placebo group (11.9 vs. 5.9 days, *P* = 0.025). Ninety-five percent of the subjects in the topiramate group were classified as responders (i.e., \>50% reduction in migraine frequency) as compared with 52% in the placebo group (*P* = 0.002). Moreover, topiramate was associated with a lower degree of functional disability than placebo. The authors reported a statistically significant difference between the two groups in both the decrease in the PedMIDAS score (*P* = 0.003) and in school absenteeism (*P* = 0.002) \[[@CR36]\].

Cruz et al. retrospectively reviewed the records of 37 patients (mean age 14 years) with migraine. An excellent or good response (i.e., \>50% migraine reduction) with topiramate was attained in 28 patients (76%). Ten (27%) patients exhibited adverse effects \[[@CR39]\].

### Valproic acid {#Sec20}

Open-label and retrospective studies \[[@CR1], [@CR10]\] have suggested that valproic acid may be effective in the prevention of migraine in children and adolescents.

Ashrafi et al. compared the effect of sodium valproate \[10--40 mg/(kg day)\] in pediatric migraine prophylaxis with that of propranolol in an RCT that included 120 children. Both drugs significantly reduced the mean migraine frequency if compared with the pre-randomization period by 5.1 migraine days/month. Response (i.e., \>50% reduction in migraine frequency) was observed in 72% of the valproate group and in 69% of the propranolol group. Furthermore, both drugs were found to effectively reduce the severity and duration of headache and to improve the response to rescue medications (*P* value \<0.01). There was no significant difference between the two groups in any of the aforementioned therapeutic effects (*P* value \<0.05) \[[@CR40]\].

To compare the efficacy, tolerability and safety of three different doses of divalproex sodium extended-release (DVPX ER) with placebo, Apostol et al. conducted a randomized double-blind placebo-controlled trial. The study included 299 adolescents aged 12--17 years. The participants were randomized in a 1:1:1:1 ratio to receive DVPX ER 250, 500, or 1,000 mg once daily or placebo. The median reduction in the migraine rate was slight and similar in all four groups in the study (1.7 migraine days in the placebo, 250 and 1,000 mg divalproex groups, and 1.4 in the 500 mg group). Response (i.e., \>50% reduction in migraine frequency) was 46% in the placebo group as compared with 41, 36 and 51% in the DVPX ER 250 mg, 500 or 1,000 mg groups, respectively. DVPX ER was not superior to placebo in the migraine-related quality of life measures either, as assessed by the PedMIDAS \[[@CR41]\].

A fourth OL study was conducted on 241 adolescents aged 12--17 years with migraine. The DVPX ER dose range was 250--1,000 mg daily. Efficacy was based on the number of migraine headache days reported in the subjects' headache diaries over sequential 4-week periods for the duration of the trial. DVPX ER treatment was associated with a 75% decrease (from 4.0 to 1.0) in the median number of headache days over a 4-week period between the first and the fourth months of the study \[[@CR42]\].

### Levetiracetam {#Sec21}

Since 2004, two OL studies have been conducted to evaluate the efficacy and safety of levetiracetam in pediatric migraine \[[@CR43], [@CR44]\]. The first study is a retrospective study in which levetiracetam was assessed in 19 patients (mean age 12 years) at doses of 125--250 mg t.i.d. The mean frequency of headache attacks, which was 6.3/month before treatment, fell to 1.7/month after treatment (*P* \< 0.0001). The migraine attacks disappeared in 52% of the patients during the treatment, though 10.5% discontinued the treatment owing to side effects \[[@CR43]\].

The second OL study included 20 pediatric patients (6--17 years). Levetiracetam dosages ranged from 20 to 40 mg/(kg day). The primary outcome measure was response (i.e., ≥50% reduction in monthly headache frequency). Eighteen of the 20 patients responded positively to levetiracetam, with a reduction of over 50% reduction in the monthly headache frequency (90% response rate) and a significant difference after treatment. The PedMIDAS revealed a significant decrease in the disability scores following levetiracetam treatment. The drug was well tolerated by the participants; the only adverse effects reported being irritability, aggressiveness and mild memory problems (15%) \[[@CR44]\].

### Zonisamide {#Sec22}

A retrospective chart review was conducted to study the efficacy of zonisamide in pediatric migraine prophylaxis. Twelve patients were identified (mean age 13.5 years). Eight patients responded positively to zonisamide, with a reduction of over 50% in the number of headaches if compared with the pretreatment values. Zonisamide was well tolerated, with only two patients reporting adverse effects that consisted in weight loss and behavioral changes \[[@CR45]\].

According to our search, no RCTs, CCTs or OL studies designed to assess the efficacy and safety of antidepressants (amitriptyline and trazodone), b-blockers (propranolol and timolol) and other antihypertensive agents, such as clonidine, have been conducted on adolescent and childhood migraine since 2004 (Table [4](#Tab4){ref-type="table"}).

The evidence levels of all the aforementioned prophylactic drugs are shown in Table [4](#Tab4){ref-type="table"}.

Conclusions {#Sec23}
===========

Few advances have been made in the treatment of pediatric migraine since 2004. As regards the acute phase treatment, prospects are unfortunately not very promising; the only drugs that are effective and safe in children being ibuprofen (Level A), acetaminophen (Level B), and sumatriptan NS (Level A). Zolmitriptan NS, which has recently been investigated, proved to be more effective than placebo (Level B). Almotriptan was approved by the FDA for the acute treatment of adolescent migraine even more recently (Table [3](#Tab3){ref-type="table"}).

As regards prophylactic treatment, topiramate has recently displayed a good level of efficacy, safety and tolerance (Level A), while flunarizine (Level A) and valproate (Level B) were already included in the previously published guidelines \[[@CR7]--[@CR9]\].

Further researches are warranted to shed more light on the underlying mechanisms of migraine and provide new treatment options designed to raise the efficacy and safety levels of currently available drugs. Moreover, additional RCTs and more controlled data are needed to help clinicians choose the most appropriate drugs for the treatment of this common clinical problem. In this regard, new and innovative study designs are required to minimize the high placebo response observed in the pediatric population.

This Tutorial partly results from the lesson of the Author (PP) at the Master in Headache Medicine, Sapienza University of Rome, during the academic year 2009--2010 (<http://w3.uniroma1.it/headache>). This Academic Educational activity is done under the supervision of Lifting The Burden---WHO Global Campaign against Headache---Working Group for Specialist Education (SEWG) (<http://www.who.int/mental_health/neurology/headache/en/>; <http://www.l-t-b.org>).
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